News

Transgene S.A.: Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer
Phase I part showed 100% Disease-Free Survival (DFS) after a minimum of 2-year follow-up - providing clinical proof of principle for TG4050 Randomization of all patients expected to be completed by en ...